Bringing protective ApoE2 protein to APOE4 and Alzheimer’s brains
Reshaping ApoE4 and Alzheimer's Brains with ApoE2
This project will see if giving a human ApoE2 protein to brains with the risky APOE4 gene can boost brain metabolism and protect against Alzheimer’s changes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kansas Lawrence NIH-funded |
| Lab location | 1 site (Lawrence, United States) |
| Project ID | NIH-11238556 on NIH RePORTER |
What this research studies
If you or a loved one carry the APOE4 gene or have Alzheimer’s, this work aims to use the protective ApoE2 protein to strengthen the brain. The team has made a human-compatible ApoE2 protein and a noninvasive way to help it cross the blood-brain barrier by changing cadherin interactions. They will test the approach in newly developed humanized mouse models that mimic common and familial forms of Alzheimer’s to measure effects on glucose use, protein balance, and synapses. The goal is to move from these preclinical steps toward treatments that could benefit people in the future.
Who could benefit from this research
Good fit: Ideal candidates would be people with Alzheimer’s disease or those at high genetic risk because they carry the APOE ε4 variant who are willing to engage with early translational research.
Not a fit: People without APOE4 or those with non‑Alzheimer’s forms of dementia are less likely to benefit from this specific ApoE2‑focused approach.
Why it matters
Potential benefit: If successful, this approach could slow or prevent Alzheimer’s progression in APOE4 carriers by improving brain energy use, protein health, and synaptic function.
How similar studies have performed: Previous research shows ApoE2 is linked to protection and gene‑delivery approaches have helped in preclinical models, but direct protein replacement and cadherin‑based blood‑brain barrier delivery are relatively new and not yet tested in humans.
Where this research is happening
Lawrence, United States
- University of Kansas Lawrence — Lawrence, United States (Active)
Researchers
- Principal investigator: Zhao, Liqin — University of Kansas Lawrence
- Study coordinator: Zhao, Liqin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.